Difficulties in maintaining potassium homeostasis in patients with heart failure

Clinical Cardiology

Volumn 29, Issue 9, 2006, Pages 388-392

  Dursun, Ihsan ^a,b   Sahin, Mahmut ^a  

^a ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Potassium and drugs; Potassium and heart failure; Potassium imbalance

Indexed keywords

ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARDIAC GLYCOSIDE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HEPARIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; MAGNESIUM SULFATE; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRIAMTERENE; VALSARTAN;

CATECHOLAMINE RELEASE; CREATININE BLOOD LEVEL; DIGITALIS INTOXICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LOW DRUG DOSE; MAGNESIUM DEFICIENCY; MORTALITY; POTASSIUM BALANCE; POTASSIUM BLOOD LEVEL; RENIN RELEASE; REVIEW; SUDDEN DEATH; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TORSADE DES POINTES; TREATMENT DURATION;

EID: 33748444351     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960290904     Document Type: Review

References (36)

1. Macdonald JE, Struthers AD: What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004;43:155-161
2. Halperin ML, Kamel KS: Potassium. Lancet 1998;352:135-140
3. Gennari FJ: Hypokalemia. N Engl J Med 1998;339:451-458
4. Schwinger RH, Erdmann E: Heart failure and electrolyte disturbances. Methods Find Exp Clin Pharmacol 1992;14:315-325
5. Bristow MR, Port JD, Kelly RA: Treatment of heart failure: Pharmacological methods. In Heart Disease. A Textbook of Cardiovascular Medicine, 6th ed. (Eds. Braunwald E, Zipes DP, Libby P), pp. 562-599. Philadelphia: W.B. Saunders, 2001
6. Remme WJ, Swedberg K: Task force for the diagnosis and treatment of chronic heart failure. Eur Heert J 2001;22:1527-1560
7. Khan MG: Cardiac Drug Therapy, 6th ed. Philadelphia: W.B. Saunders, 2003
8. He FJ, MacGregor GA: Beneficial effects of potassium. Br Med J 2001;323: 497-501
9. Sheehan JP, Seelig MS: Interactions of magnesium and potassium in the pathogenesis of cardiovascular disease. Magnesium 1984;3:301-314
10. Tong GM, Rude RK: Magnesium deficiency in critical illness. J Intens Care Med 2005;20(1):3-17
11. Vester EG: Clinico-electrophysiologic effects of magnesium, especially in supraventricular tachycardia. Herz 1997;22(suppl 1):40-50
12. Khan IA: Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002;112(1):58-66
13. Eriksson JW, Carlberg B, Hillön V: Life-threatening ventricular tachycardia due to liquorice-induced hypokalemia. J Intern Med 1999;245:307-310
14. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-592
15. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW III, Young JB, Probstfield J: Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996;131(2):350-355
16. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-1676
17. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100(23):2312-2318
18. The NETWORK Investigators: Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparison. Eur Heart J 1998;19(3): 481-489
19. Brunner HR, Weaber B, Nussberger J: Angiotensin-converting enzyme inhibitors. In Cardiovascular Drug Therapy, 2nd ed. (Ed. Messerli FH), pp. 696-697. Philadelphia: W. B. Saunders, 1996
20. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, for the CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure. The CHARM-Overall programme. Lancet 2003;362:759-766
21. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, for the CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-771
22. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, for the Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906
23. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomized trial. Lancet 2002;360:752-760
24. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675
25. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE Snavely DB, Chang PI: Randomized trial of losartan versus captopril in patients over 65 with heart failure: Evaluation of Losartan in Elderly Study (ELITE). Lancet 1997;349:747-752
26. Podrid PJ: Potassium and ventricular arrhythmias. Am J Cardiol 1990;65: 33E-44E;discussion 52E
27. Madias JE, Shah B, Chintalapally G, Chalavarya G, Madias NE: Admission serum potassium in patients with acute myocardial infarction: Its correlates and value as a determinant of in-hospital outcome. Chest 2000;118:904-913
28. Foo K, Sekhri N, Deaner A, Knight C, Suliman A, Ranjadayalan K, Timmis AD: Effect of diabetes on serum potassium concentrations in acute coronary syndromes. Heart 2003;89:31-35
29. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
30. Struthers AD, MacDonald TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61: 663-670
31. Gross P, Pistrosch F: Hyperkalemia: Again. Nephrol Dial Transplant 2004; 19:2163-2166
32. Schepkens H, Vanholder R, Billiouvv JM, Lameire N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 2001;110: 438-441
33. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-551
34. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, selective aldosterone blocker in patients with left-ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
35. Mason DT, Zelis R, Lee G, Hughes JL, Spann JF, Amsterdam EA: Current concepts and treatment of digitalis toxicity. Am J Cardiol 1971;27:546-559
36. Day JRS, Chaudhry AN, Hunt I, Taylor KM: Heparin-induced hyperkalemia after cardiac surgery. Ann Thorac Surg 2002;74:1698-1700